Idiopathic Pulmonary Fibrosis and Hypersensitive Pneumonitis: A Fresh View on The Role of Genetic and Epigenetic Factors in The Development and Course of Diseases ; Идиопатический легочный фиброз и гиперсенситивный пневмонит: новый взгляд на роль генетических и эпигенетических факторов в развитии и течении заболеваний

Συγγραφείς: E. E. Arkhangelskaya, S. V. Lyamina, E. O. Kozhevnikova, I. V. Kozlova, T. G. Shapovalova, G. L. Yurenev, Е. Е. Архангельская, С. В. Лямина, Е. О. Кожевникова, И. В. Козлова, Т. Г. Шаповалова, Г. Л. Юренев

Συνεισφορές: The authors claim a lack of funding for the study, Авторы заявляют об отсутствии финансирования при проведении исследования

Πηγή: The Russian Archives of Internal Medicine; Том 14, № 6 (2024); 405-418 ; Архивъ внутренней медицины; Том 14, № 6 (2024); 405-418 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: терапия, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, familial pulmonary fibrosis, genetic, epigenetic, MUC5B, TERT, telomeres, surfactant, therapy, идиопатический легочный фиброз, гиперсенситивный пневмонит, семейный легочный фиброз, генетический, эпигенетический, теломеры, сурфактант

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1876/1367; https://www.medarhive.ru/jour/article/view/1876/1374; Данные генетического регистра. [Электронный ресурс]. URL: https://www.ncbi.nlm.nih.gov/gtr/tests/552741/. (дата обращения 11. 09. 2024).; Интерстициальные болезни легких: практическое руководство под ред. Н.А. Мухина. М.: Литера. 2007; 432 с.; Визель А.А., Горблянский Ю.Ю., Илькович М.М. и др. Фиброзирующий саркоидоз: от понимания к перспективе лечения. Практическая пульмонология. 2021; 1: 61-73.; Бирюкова С.С., Вишневский А.Г., Гимпельсон В.Е. и др. Как увеличить человеческий капитал и его вклад в экономическое и социальное развитие. Тезисы докладов к ХIX Апрельской международной научной конференции по проблемам развития экономики и общества, под ред. Кузьминова Я.И., Овчаровой Л.Н., Якобсона Л.И. Москва, Изд. дом Высшей школы экономики. 2018; 38-46.; Adegunsoye A., Oldham J.M., Fernandez Perez E.R., et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017; 3: 00016–2017. doi:10.1183/23120541.00016-2017.; Alder J.K., Stanley S.E., Wagner C.L., et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015; 147: 1361–8. doi:10.1378/chest.14-1947.; Allen R.J., Porte J., Braybrooke R., et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 2017; 5: 869–80. doi:10.1016/S2213-2600(17)30387-9.; Antoine M.H., Mlika M. Interstitial Lung Disease.In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024. [Electronic resource]. URL: https://www.ncbi.nlm.nih.gov/books/NBK541084/ (date of the application: 02. 05. 2024).; Avci E., Sarvari P., Savai R., et al. Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets? Int J Mol Sci. 2022; 23(1): 546. doi:10.3390/ijms23010546.; Raghu G., Remy-Jardin M., Myers J.L., et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5): e44–e68. doi:10.1164/rccm.201807-1255ST.; Bartczak K., Białas A.J.; Kotecki M.J., et al. More than a Genetic Code: Epigenetics of Lung Fibrosis. Mol. Diagn. Ther. 2020; 24: 665–681. doi:10.1007/s40291-020-00490-7.; Chen Y., Huang Z., Bao Y., et al. Increased p300/CBP expression in acute respiratory distress syndrome is associated with interleukin-17 and prognosis. Clin. Respir. J. 2020; 14: 791–799. doi:10.1111/crj.13197.; Cogan J.D., Kropski J.A., Zhao M., et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med. 2015; 191: 646–55. doi:10.1164/rccm.201408-1510OC.; Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020; 8: 585–96. doi:10.1016/S2213-2600(20)30105-3].; Dai J., Cai H., Li H., et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology. 2015; 20: 947–52. doi:10.1111/resp.12566.; Dickson R.P., Erb-Downward J.R., Martinez F.J., et al. The microbiome and the respiratory tract. Annu Rev Physiol. 2016; 78: 481–504. doi:10.1146/annurev-physiol-021115-105238.; Ding Q., Luckhardt T., Hecker L., et al. New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Drugs. 2011; 71: 981–1001. doi:10.2165/11591490-000000000-00000.; Falfán-Valencia R., Camarena A., Pineda C.L., et al. Genetic susceptibility to multicase hypersensitivity pneumonitis is associated with the TNF-238 GG genotype of the promoter region and HLADRB1*04 bearing HLA haplotypes. Respir Med. 2014; 108: 211–217. doi:10.1016/j.rmed.2013.11.004.; Fingerlin T.E., Murphy E., Zhang W., et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet, 2013; 45: 613–20. doi:10.1038/ng.2609.; Garbuzenko O.B., Ivanova V., Kholodovych V., et al. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomed. Nanotechnol. Biol. Med. 2017; 13: 1983–1992. doi:10.1016/j.nano.2017.04.005; Hannum G., Guinney J., Zhao L., et al. Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. Mol. Cell. 2013; 49: 359–367. doi:10.1016/j.molcel.2012.10 .016.; Hao Y., Bates S., Mou H., et al. Genome-Wide Association Study: Functional Variant rs2076295 Regulates Desmoplakin Expression in Airway Epithelial Cells. Am J Respir Crit Care Med. 2020; 202(9): 1225-1236. doi:10.1164/rccm.201910-1958OC.; Herazo-Maya J.D., Sun J., Molyneaux P.L., et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med. 2017; 5: 857–68. doi:10.1016/S2213-2600(17)30349-1.; Hewitt R.J., Molyneaux P.L. The respiratory microbiome in idiopathic pulmonary fibrosis. Ann Transl Med. 2017; 5: 250. doi:10.21037/atm.2017.01.56.; Huang Y., Ma S.F., Espindola M.S., et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017; 196: 208–19. doi:10.1164/rccm.201607-1525OC.; Killian H., Ozaki M., Philippot Q., et al. A roadmap to precision treatments for familial pulmonary fibrosis. eBioMedicine. EBioMedicine. 2024; 104: 105135. doi:10.1016/j.ebiom.2024.105135.; Justet A., Klay D., Porcher R., et al. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. Eur. Respir. J. 2021; 57: 2003198. doi:10.1183/13993003.03198-2020.; Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2003; 29(3): S32–S36.; Kannengiesser C., Borie R., Ménard C., et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J. 2015; 46: 474–85. doi:10.1183/09031936.00040115; King Jr T.E., Bradford W.Z., C astro-Bernardini S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–92. doi:10.1056/NEJMoa1402582.; Koh H.B., Scruggs A.M., Huang S.K. Transforming growth factor-β1 increases DNA methyltransferase 1 and 3a ex-pression through distinct post-transcriptional mechanisms in lung fibroblasts. J. Biol. Chem. 2 016; 291: 19287–19298.; Krishna R. Genetic Testing in Interstitial Lung Disease: Potential Benefits and Unintended Risks. Curr Pulmonol Rep. 2023; 12: 228–238.; Kropski J.A., Mitchell D.B., Markin C., et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumon ia. Chest. 2014; 146: e1–7. doi:10.1378/chest.13-2224.; Kwapiszewska G., Gungl A., Wilhelm J., et al. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. Eur. Respir. J. 2018; 52: 1800564. doi:10.1183/13993003.00564-2018.; Ley B., Newton C.A., Arnould I., et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017; 5: 639–47. doi:10.1016/S2213-2600(17)30216-3.; Martinez F.J., Collard H.R., Pardo A., et al. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Prim. 2017; 3: 17074. doi:10.1038/nrdp.2017.74.; Mathai S.K., Pedersen B.S., Smith K., et al. Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016; 193(10): 1151-60. doi:10.1164/rccm.201509-1863OC.; Michalski J.E., Schwartz D.A. Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis. J Inflamm Res. 2021; 13: 1305-1318. doi:10.2147/JIR.S280958.; Molyneaux P.L., Maher T.M. Respiratory microbiome in IPF: cause, effect, or bio marker? Lancet Respir Med. 2014; 2: 511-513. doi:10.1016/S2213-2600(14)70088-8.; Molyneaux P.L., Willis-Owen S.A.G, Cox M.J., et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017; 195: 1640–50. doi:10.1164/rccm.201607-1408OC.; Nakao A., Fujii M., Matsumura R., et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Investig. 1999; 104: 5–11. doi:10.1172/JCI6094.; Newton C.A., Molyneaux P.L., Oldham J.M. Clinical Genetics in Interstitial Lung Disease.Front. Med. 2018; 5: 116. doi:10.3389/fmed.2018.00116.; Oldham J.M., Ma S.F., Martinez F.J., et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015; 192: 1475–82. doi:10.1164/rccm.201505-1010OC.; Olson A.L., Gifford A.H., Inase N., et al. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur. Respir. Rev. 2018; 27(150): 180077. doi:10.1183/16000617.0077-2018.; Olson A.L., Brown K.K., Swi gris J.J. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas. 2016; 7: 29–35. doi:10.2147/PROM.S74857.; Povedano J.M., Martinez P., Serrano R., et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. eLife. 2018; 7: e31299. doi:10.7554/eLife.31299.; Raghu G., Chen S.-Y., Hou Q., et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016; 48: 179–86. doi:10.1183/13993003.01653-2015.; Roy M.G., Livraghi-Butrico A., Fletcher A.A., et al. Muc5b is required for airway defence. Nature. 2014; 505: 412–6. doi:10.1038/nature12807.; Rubio K., Singh I., Dobersch S., Sarvari P., Günther S., Cordero J., Mehta A., Wujak L., Cabrera-Fuentes H., Chao C.-M., et al. Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopat hic pulmonary fibrosis. Nat. Commun. 2019; 10: 1–16. doi:10.1038/s41467-019-10066-7.; Ryerson C.J., Vittinghoff E., Ley B., et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest.2014; 145: 723–8. doi:10.1378/chest.13-1474.; Sakamoto S., Yazawa T., Baba Y., et al. Keratinocyte Growth Factor Gene Transduction Ameliorates Pulmonary Fibrosis Induced by Bleomycin in Mice. Am. J. Respir. Cell Mol. Biol. 2011; 45: 489–497. doi:10.1165/rcmb.2010-0092OC.; Salisbury M.L., Han M.K., Dickson R.P., Molyneaux PL. Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med. 2017; 23: 404–10. doi:10.1097/MCP.0000000000000399.; Schwartz D.A. Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways. Ann. Am. Thorac. Soc. 2018; 15(S3): S192–S197. doi:10.1513/AnnalsATS.201802-144AW.; Seibold M.A., Wise A.L., Speer M.C., et al. A common M UC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364: 1503–12. doi:10.1056/NEJMoa1013660.; Selman M., Pardo A., Barrera L., et al. Gene Expression Profiles Distinguish Idiopathic Pulmonary Fibrosis from Hypersensitivity Pneumonitis. Am. J. Respir. Crit. Care Med. 2006; 173: 188–198. doi:10.1164/rccm.200504-644OC.; Sheu C.-C., Chang W.-A., Tsai M.-J., et al. Gene Expression Changes Associated with Nintedanib Treatment in Idiopathic Pulmonary Fibrosis Fibroblasts: A Next-Generation Sequencing and Bioinformatics Study. J. Clin. Med. 2019; 8: 308. doi:10.3390/jcm8030308.; Steele M.P., Speer M.C., Loyd J.E., et al. The Clinical and Pathologic Features of Familial Interstitial Pneumonia (FIP) Am. J. Respir. Crit. Care Med. 2005; 172: 1146–1152. doi:10.1164/rccm.200408-1104OC.; Stuart B.D., Choi J., Zaidi S., et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet. 2015; 47: 512–7. doi:10.1038/ng.3278.; Stuart B.D ., Lee J.S., Kozlitina J., et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014; 2: 557–65. doi:10.1016/S2213-2600(14)70124-9.; Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease? Proc. Am. Thorac. Soc. 2006; 3: 293–298. doi:10.1513/pats.200512-131TK.; Thannickal V.J., Henke C.A., Horowitz J.C., et al. Matrix biology of idiopathic pulmonary fibrosis: A workshop report of the national heart, lung, and blood institute. Am. J. Pathol. 2014; 184: 1643–1651. doi:10.1016/j.ajpath.2014.02.003.; Tirelli C., Morandi V., Valentini A., et al. Multidisciplinary Approach in the Early Detection of Undiagnosed Connective Tissue Diseases in Patients With Interstitial Lung Disease: A Retrospective Cohort Study. Front. Med. 2020; 7: 11. doi:10.3389/fmed.2020.00011.; Tirelli C., Pesenti C., Miozzo M., et al. The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review. Diagnostics. 2022; 12: 3107.; Watanabe M., Ebina M., Orson F.M., et al. Hepatocyte Growth Factor Gene Transfer to Alveolar Septa for Effective Suppression of Lung Fibrosis. Mol. Ther. 2005; 12: 58–67. doi:10.1016/j.ymthe.2005.02.019.; Yuan J., Li P., Pan H., et al. miR-542-5p Attenuates Fibroblast Activation by Targeting Integrin α6 in Silica-Induced Pulmonary Fibrosis. Int. J. Mol. Sci. 2018; 19: 3717. doi:10.3390/ijms19123717.; Zhang S., Liu H., Liu Y., et al. miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis. Int. J. Mol. Sci. 2017; 18: 633. doi:10.3390/ijms18030633.; Zhang Y.S., Tu B., Song K. et al. Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives. Cell Signal. 2023; 110: 110842. doi:10.1016/j.cellsig.2023.110842.; https://www.medarhive.ru/jour/article/view/1876

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1876
https://doi.org/10.20514/2226-6704-2024-14-6-405-418

Modern concepts of clinical variants and features of hypersensitivity pneumonitis in children ; Современные представления о клинических вариантах и особенностях гиперсенситивного пневмонита у детей

Συγγραφείς: N. S. Lev, Yu. L. Mizernitskiy, Н. С. Лев, Ю. Л. Мизерницкий

Πηγή: Meditsinskiy sovet = Medical Council; № 12 (2023); 182-191 ; Медицинский Совет; № 12 (2023); 182-191 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: легочный фиброз, adolescents, interstitial lung disease, hypersensitivity pneumonitis, pulmonary fibrosis, подростки, интерстициальные болезни легких, гиперсенситивный пневмонит

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7670/6804; Raghu G., Remy-Jardin M., Ryerson C.J., Myers J.L., Kreuter M., Vasakova M. et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/ JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-e69. https://doi.org/10.1164/rccm.202005-2032ST.; Авдеев С.Н. Гиперчувствительный пневмонит. Пульмонология. 2021;(1):88-99. https//doi.org/10.18093/0869-0189-2021-31-1-88-99.; Selman M., Pardo A., King T.E.Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314-324. https://doi.org/10.1164/rccm.201203-0513CI.; Vasakova M., Selman M., Morell F., Sterclova M., Molina-Molina M., Raghu G. Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment. Am J Respir Crit Care Med. 2019;200(3):301-308. https//doi.org/10.1164/rccm.201903-0541RR.; Fernandez Perez E.R., Kong A.M., Raimundo K., Koelsch T.L., Kulkarni R., Cole A.L. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc. 2018;15(4):460-469. https//doi.org/10.1513/AnnalsATS.201704-288OC.; Buchvald F., Retersen B.L., Damgaard K., Deterding R., Langston C., Fan L.L. et al. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. Pediatr Pulmonol. 2011;46(11):1098-1107. https://doi.org/10.1002/ppul.21479.; Clement А., Nathan N., Epaud R., Fauroux В., Corvol Н. Interstitial lung diseases in children. Orphanet J Rare Dis. 2010;5(22):1750-1172. https://doi.org/10.1186/1750-1172-5-22.; Jordan L.E., Guy E. Raediatric feather duvet hypersensitivity pneumonitis. BMJ Case Rep. 2015;2015:bcr2014207956. https://doi.org/10.1136/bcr-2014-207956.; Лев Н.С., Мизерницкий Ю.Л. Клинические варианты интерстициальных болезней легких в детском возрасте. М.: Медпрактика-М; 2021. 368 с.; Higashino-Kameda M., Yabe-Wada T., Matsuba S., Takeda K., Anzawa K., Mochizuki T. et al. A critical role of Dectin-1 in hypersensitivity pneumonitis. Inflamm Res. 2016;65(3):235-244. https://doi.org/10.1007/s00011-015-0910-1.; Girard M., Is^l-Assayag E., Cormier Y. Impaired function of regulatory T-cells in hypersensitivity pneumonitis. Eur Respir J. 2011;37(3):632-639. https://doi.org/10.1183/09031936.00055210.; Barrera L., Mendoza F., Zuniga J., Estrada A., Zamora A.C., Melendro E.I. et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2008;177(1):44-55. https://doi.org/10.1164/rccm.200701-093OC.; Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235-238. https//doi.org/10.1038/nature04753.; Simonian R.L., Roark C.L., Wehrmann F., Lanham A.K., Diaz del Valle F., Born W.K. et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol. 2009;182(1):657-665. https//doi.org/10.4049/jimmunol.182.1.657.; Garda de Alba C., Buendia-Roldan I., Salgado A., Becerril C., Ramkez R., Gonzalez Y. et al. Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J Respir Crit Care Med. 2015;191(4):427-436. https//doi.org/10.1164/rccm.201407-1334OC.; Ohshimo S., Bonella F., Guzman J., Costabel U. Hypersensitivity Pneumonitis. Immunol Allergy Clin North Am. 2012;32(4):537-556. https://doi.org/10.1016/j.iac.2012.08.008.; Hirschmann J.V., Pipavath S.N.J., Godwin J.D. Hypersensitivity Pneumonitis: historical, Clinical, and Radiologic Review. Radiographics. 2009;29(7):1921-1938. https://doi.org/10.1148/rg.297095707.; Aquino-Galvez A., Camarena A., Montano M., Juarez A., Zamora A.C., Gonzalez-Avila G. et al. Transporter associated with antigen processing (TAP) 1 gene polymorphisms in patients with hypersensitivity pneumonitis. Exp Mol Pathol. 2008;84(2):173-177. https//doi.org/10.1016/j.yexmp.2008.01.002.; Fiddler C., Parfrey H. Hypersensitivity pneumonitis. In: Thillai М. Clinical Handbook of Interstitial Lung Disease. London: Taylor & Francis Group, LLC International Standard Book; 2018. 547 р.; Gandhi C.K., Chen C., Amatya S., Yang L., Fu C., Zhou S. et al. SNP and haplotype interaction models reveal association of surfactant protein gene polymorphisms with hypersensitivity pneumonitis of mexican population. Front Med. 2021;7:588404. https://doi.org/10.3389/fmed.2020.588404.; King T.E. Classification and clinical manifestations of hypersensitivity pneumonitis. 2009.; Hilman B.C., Amaro-Galvez R. Diagnosis of and treatment of Interstitial lung disease in children. Pediatr Resir Rev. 2004;5(2):101-107. https://doi.org/10.1016/j.prrv.2004.01.001.; Morisset J., Johannson K.A., Jones K.D., Wolters P.J., Collard H.R., Walsh S.L.F. et al. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018;197(8):1036-1044. https//doi.org/10.1164/rccm.201710-1986OC.; Lacasse Y., Selman M., Costabel U., Dalphin J.-C., Ando M., Morell F. et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168(8):952-958. https//doi.org/10.1164/rccm.200301-137OC.; Patel R.A., Sellami D., Gotway M.B., Golden J.A., Webb W.R. Hypersensitivity pneumonitis: patterns on high-resolution CT. J Comput Assist Tomogr. 2000;24(6):965-970. https//doi.org/10.1097/00004728-200011000-00025.; Мизерницкий Ю.Л. (ред.). Атлас рентгенодиагностики острых и хронических неспецифических заболеваний легких у детей. М.: Медпрактика-М; 2014. 276 с.; Silva C.I.S., Muller N.L., Fujimoto K., Kato S., Ichikado K., Taniguchi H. et al. Acute exacerbation of chronic interstitial pneumonia: High-resolution computed tomography and pathologic findings. J Thorac Imaging. 2007;22(3):221-229. https//doi.org/10.1097/01.rti.0000213588.52343.13.; Dias O.M., Baldi B.G., Pennati F., Aliverti A., Chate R.C., Sawamura M.V.Y. et al. Computed tomography in hypersensitivity pneumonitis: main findings, differential diagnosis and pitfalls. Expert Rev Respir Med. 2018;12(1):5-13. https//doi.org/10.1080/17476348.2018.1395282.; Franquet T., Hansell D.M., Senbanjo T., Remy-Jardin M., Muller N.L. Lung cysts in subacute hypersensitivity pneumonitis. J Comput Assist Tomogr. 2003;27(4):475-478. https//doi.org/10.1097/00004728-200307000-00003.; Gimenez A., Storrer K., Kuranishi L., Soares M.R., Ferreira R.G., Pereira C.A.C. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018;73(4):391-392. https//doi.org/10.1136/thoraxjnl-2017-210035.; Travis W.D. Handling and analysis of bronchoalveolar lavage and lung biopsy specimens with approach to patterns of lung injury. 2007.; Costabel U., Bonella F., Guzman J. Chronic hypersensitivity pneumonitis. Clin Chest Med. 2012;33(1):151-163. https//doi.org/10.1016/j.ccm.2011.12.004.; Myers J.L. Hypersensitivity pneumonia: The role of lung biopsy in diagnosis and management. Mod Pathol. 2012;25(1):S58-67. https//doi.org/10.1038/modpathol.2011.152.; Grunes D., Beasley M.B. Hypersensitivity pneumonitis: A review and update of histologic findings. J Clin Pathol. 2013;66(10):888-895. https://doi.org/10.1136/jclinpath-2012-201337.; Trahan S., Hanak V., Ryu J.H., Myers J.L. Role of surgical lung biopsy in sepa-rating chronic hypersensitivity pneumonia from usual interstitial pneumo-nia/idiopathic pulmonary fibrosis: Analysis of 31 biopsies from 15 patients. Chest. 2008;134(1):126-132. https//doi.org/10.1378/chest.08-0033.; Bush A., Cunningham S., de Blic J., Barbato A., Clement A., Epaud R. et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2O15;7O(11):1078-1084. https//doi.org/10.1136/thoraxjnl-2015-207349.; Wijsenbeek M., Kreuter M., Olson A., Fischer A., Bendstrup E., Wells C.D. et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. https://doi.org/10.1080/03007995.2019.1647040.; Deterding R.R., DeBoer E.M., Cidon M.J., Cidon M.J., Robinson T.E., Warburton D., Young L.R. Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis. Am J Respir Crit Care Med. 2O19;2O0(10):1219-1227. https//doi.org/10.1164/rccm.201903-0544CI.; Лев Н.С., Мизерницкий Ю.Л. Современные принципы и перспективы медикаментозной терапии интерстициальных заболеваний легких у детей. Российский вестник перинатологии и педиатрии. 2022;(3):18-22. Режим доступа: https://www.ped-perinatology.ru/jour/article/view/1647.; Лев Н.С., Мизерницкий Ю.Л., Шатоха П.А., Грознова О.С. Трансплантация легких у подростка с легочным фиброзом в исходе интерстициальной болезни легких (гиперсенситивного пневмонита). Педиатрия. Журнал имени ГН. Сперанского. 2020;(6):287-293. https//doi.org/10.24110/0031-403X-2020-99-6-287-293.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/7670
https://doi.org/10.21518/ms2023-152

Гиперсенситивный пневмонит: клинический случай ; Hypersensitive pneumonitis:clinical case

Συγγραφείς: Belousova, E. V., Gordeeva, A. E., Khachaturov, A. S., Tsvetkov, D. K., Sabadash, E. V., Белоусова, Е. В., Гордеева, А. Е., Хачатуров, А. С., Цветков, Д. К., Сабадаш, Е. В.

Πηγή: Сборник статей

Θεματικοί όροι: HYPERSENSITIVE PNEUMONITIS, EXOGENOUS ALLERGIC ALVEOLITIS, ГИПЕРСЕНСИТИВНЫЙ ПНЕВМОНИТ, ЭКЗОГЕННЫЙ АЛЛЕРГИЧЕСКИЙ АЛЬВЕОЛИТ

Περιγραφή αρχείου: application/pdf

Relation: Сборник статей "V Международная (75 Всероссийская) научно-практическая конференция "Актуальные вопросы современной медицинской науки и здравоохранения". 2020. №2; http://elib.usma.ru/handle/usma/3018

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/3018

Hypersensitivity pneumonitis in children

Συγγραφείς: N. S. Lev

Πηγή: Медицинский совет, Vol 0, Iss 1, Pp 81-87 (2015)

Θεματικοί όροι: дети, интерстициальные болезни легких, гиперсенситивный пневмонит, гиперчувствительный пневмонит, глюкокортикостероиды, children, interstitial lung disease, hypersensitivity pneumonitis, glucocorticosteroids, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/497; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/16cb6f5764e74022a79e36dc76877c32

Гиперсенситивный пневмонит (экзогенный аллергический альвеолит) у детей

Συγγραφείς: Ашерова И.К., Овсянников Д.Ю., Илларионова Т.Ю.

Πηγή: Pediatriya - Zhurnal im G.N. Speranskogo

Θεματικοί όροι: hypersensitivity pneumonitis, exogenous allergic alveolitis, children, diagnostics, therapy, гиперсенситивный пневмонит, экзогенный аллергический альвеолит, дети, диагностика, терапия

Relation: https://repository.rudn.ru/records/article/record/80000/

Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/80000/